Pattern Bioscience is a privately held in vitro diagnostics company founded in 2016 to help combat the problem of antibiotic resistance. Pattern is developing a next-generation clinical microbiology platform based on its patented phenotypic single-cell technology that can rapidly identify pathogens and determine their antibiotic response without the need for traditional time-consuming culture steps. Pattern's Digital CultureTM technology relies on functional endpoints that encompass all possible resistance mechanisms, resulting in more comprehensive and reliable diagnoses compared to rapid genotypic tests. The platform will deliver more reliable diagnoses days faster than the current standard of care.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/14/20	$9,000,000	Series B-1	Illumina Ventures Omnimed Capital	undisclosed
04/27/23	$28,700,000	Series C	Antimicrobial Resistance Action Fund Daleshaw Ltd Illumina Ventures Omnimed Capital	undisclosed